Detalles de la búsqueda
1.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 924-937, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31122901
2.
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases.
JTO Clin Res Rep
; 4(4): 100483, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37025119
3.
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC.
JTO Clin Res Rep
; 3(7): 100341, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35756755
4.
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Lancet
; 366(9496): 1527-37, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16257339
5.
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
Clin Pharmacol Ther
; 110(5): 1162-1163, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34365647
6.
Tumor volume measurement error using computed tomography imaging in a phase II clinical trial in lung cancer.
J Med Imaging (Bellingham)
; 3(3): 035505, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27660808
7.
A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens.
Cancer Chemother Pharmacol
; 52(2): 113-8, 2003 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12783201
8.
Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
Lung Cancer
; 86(1): 67-72, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25154982
9.
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
J Thorac Oncol
; 9(6): 848-55, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24807156
10.
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
J Clin Oncol
; 27(8): 1227-34, 2009 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19188680
Resultados
1 -
10
de 10
1
Próxima >
>>